She tried to claim her prize and got stuck
She tried to claim her prize and got stuck
Several hundred more migrants reached a tiny Italian island before dawn on Monday, swelling to past 2,100 the number of arrivals in some 24 hours. Italian state radio said four boats arrived at Lampedusa island after being escorted the last miles to port early Monday by Italian coast guard or custom police vessels. The 635 latest arrivals followed more than 1,400 who arrived on Sunday.
Major players in the gastrointestinal devices market are Boston Scientific, Medtronic, Fujifilm Holdings Corporation, CONMED Corporation, Stryker Corporation, Johnson and Johnson, Olympus, Cook Group, Becton, Dickinson and Company, and B.New York, May 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Gastrointestinal Devices Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06071096/?utm_source=GNW Braun Melsungen.The global gastrointestinal devices market is expected to grow from $7.438 billion in 2020 to $7.902 billion in 2021 at a compound annual growth rate (CAGR) of 6.2%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $11.594 billion in 2025 at a CAGR of 10%.The gastrointestinal devices market consists of sales of gastrointestinal devices and related services by entities (organizations, sole traders and partnerships) that manufacture gastrointestinal devices.These devices are used for the diagnosis and treatment of medical conditions related to the digestive system or the gastrointestinal tract.Some of these products include gastroscope, enteroscope, and ultrasound endoscope. Only goods and services traded between entities or sold to end consumers are included.Single-use disposable endcap of duodenoscope is increasingly being used to prevent contamination during endoscopic retrograde cholangiopancreatography (ERCP) procedures.Single-use disposable cap controls the infection and preserves the duodenoscope optics.The USFDA recommended the hospitals and clinics to shift from reusable duodenoscopes to disposable parts duodenoscopes.The USFDA also approved the duodenoscope model featuring the disposable parts such as the PENTAX Medical ED34-i10T duodenoscope in November 2019, FUJIFILM Corporation duodenoscope model ED-580XT in March 2019, Olympus TJF-Q190V Duodenoscope in January 2020.Olympus TJF-Q190V duodenoscope is used to perform the ERCP procedure with less risk of contamination due to the disposable distal endcap.The gastrointestinal devices market covered in this report is segmented by product type into GI videoscopes; biopsy devices; endoscopic retrograde cholangiopancreatography devices (ERCP); capsule endoscopy; endoscopic ultrasound; endoscopic mucosal resection (EMR); hemostasis devices; others, and by end users into hospitals; clinics and dialysis centers; ambulatory surgical center.In March 2018, Boston Scientific had acquired EMcision for an undisclosed amount.The acquisition expected to expand and strengthen Boston scientific endoscopy portfolio that includes the Habib EndoHPB probe.The Habib EndoHPB probe is a new endoscopic bipolar radiofrequency device that coagulates tissue in the gastrointestinal (GI) tract.EMcision is a medical device company located in the United Kingdom and Canada.EMcision product portfolio includes Habib EndoHPB, Habib Endolate, Habib VesCoag.The increasing prevalence of gastrointestinal diseases contributed to the growth of the gastrointestinal devices market.Gastrointestinal diseases include irritable bowel syndrome, hemorrhoids, perianal abscesses, colon polyps, and cancer among others.According to the Endoscopy Centre, every year 62 million Americans are diagnosed with any of the digestive diseases, and 2% to 6% or an estimated 3 lakhs to 5 lakhs Americans suffer from inflammatory bowel disease (IBD).According to the American College of Gastroenterology estimates, 10-15% of the adult population in the USA suffer from irritable bowel syndrome (IBS) symptoms.The increased prevalence of gastrointestinal diseases increased the demand for gastrointestinal devices to treat patients, thereby driving the market growth.High healthcare costs for treating gastrointestinal disease restrains the gastrointestinal devices market.According to the NEJM Journal Watch, a sister publication of New England Journal of Medicine, the overall healthcare expenditure for the gastrointestinal disease is around $136 billion annually which is more than heart disease healthcare expenditure ($113 billion), trauma expenditure ($103 billion), mental health expenditure ($99 billion), indicating the high expenses involved in treating gastrointestinal disease.Moreover, a database analysis by American Gastroenterological Association states that patients with inflammatory bowel diseases (IBDs), chronic liver diseases (CLDs), functional gastrointestinal disorders (FGIDs), gastrointestinal hemorrhage are hospitalized at least once and are high-need and high-cost patients contributing disproportionately to hospitalization costs.In this context, they are the ones who are accessing inpatient services and need immense care due to functional limitation increasing the expenditure.The high healthcare expenditure for gastrointestinal disease forces the majority population to refrain from receiving treatment in non-emergency cases, which negatively impacts the growth of the gastrointestinal devices market.Read the full report: https://www.reportlinker.com/p06071096/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Dublin, May 10, 2021 (GLOBE NEWSWIRE) -- The "Blow-Fill-Seal Technology Market Size, Share & Analysis, By Product, By Raw Material, And By End-Use, And By Region, Forecast To 2028" report has been added to ResearchAndMarkets.com's offering. The global blow-fill-seal technology market size is expected to reach USD 499.3 Million in 2028, and register a CAGR of 5.20% during the forecast period. Constantly growing pharmaceuticals company and rising need for a technique to prevent potential extraneous contamination is a key factor driving market revenue growth. Increasing investments for constant advancements in Blow-Fill-Seal (BFS) technologyGrowing awareness regarding prominent advantage offered by blow-fill-seal technique such as sterile and hygienic solution for dispersing products and sealing containers without or minimal human intervention in the fill/finish process among manufacturers in food and beverage, and pharmaceutical industries is a major factor driving market growth. Blow-fill-seal technique has been approved by FDA as an ideal automated process for forming, filling, and sealing containers in a continuous process with contamination.Constant developments in BFS technology is enabling contamination-free packaging of wide-range of containers such as vials with inserted caps, twist-off vials, reclose-able vials, multi-dose bottles, single dose or unit dose pre-filled syringes, as well as electrolyte and sports-drink bottles.Manufacturing of products using BFS technology requires relatively higher capital investments, which leads to high cost of the final product. This factor could hamper demand for BFS technology and hamper market growth to some extent.Some Key Findings From the Report: Among the product type segments, the bottles segment accounted for significantly high revenue share in the global market in 2020, as bottles are light-in-weight as compared to other options and are easily portable.Among the raw material segments, the Polyvinylchloride (PVC) segment accounted for significant revenue share in 2020. The Polyethylene (PE) segment is projected to register the highest CAGR during the forecast period.Among the end-use segments, the pharmaceutical segment accounted for major revenue share in the global market in 2020, and is expected to register considerably high CAGR during the forecast period. Rapidly growing pharmaceutical industry and rising demand for accurate single-dose packages, ampoules, and vials, to optimize product quality are factors expected to drive revenue growth if this segment.The food and beverages segment is expected to register considerably high revenue growth rate during the forecast period, due to growing demand for packed food and beverages, rising need for blow-fill-seal technique to disperse products in order to lower human intervention and food contamination.North America market accounted for the substantially high revenue share in 2020, due to presence of large number of major pharmaceutical companies, coupled with need for hygienic packaging to avoid contamination of drugs.Europe market accounted for significantly high revenue share in 2020, as the BFS technology was developed in Europe and it has relatively high demand in the pharmaceutical industry in the region.The Asia Pacific market is expected to register highest CAGR during the forecast period in the global blow-fill-seal technology market, due to rapidly growing various end-use industries such as food and beverages, and pharmaceuticals. Key Topics Covered: Chapter 1. Market SynopsisChapter 2. Executive Summary2.1. Summary Snapshot, 2020 - 2028Chapter 3. Indicative MetricsChapter 4. Blow-Fill-Seal Technology Market Segmentation & Impact Analysis4.1. Blow-Fill-Seal Technology Market Material Segmentation Analysis4.2. Industrial Outlook4.2.1. Market indicators analysis4.2.2. Market drivers analysis126.96.36.199. Rise in demand from healthcare and pharmaceutical sector.188.8.131.52. Shift in consumer preference against the use of food preservatives4.2.3. Market restraints analysis184.108.40.206. Cost-To-Benefit Ratio A Concern to Small Manufacturers4.3. Technological Insights4.4. Regulatory Framework4.5. ETOP Analysis4.6. Porter's Five Forces Analysis4.7. Competitive Metric Space Analysis4.8. Price trend AnalysisChapter 5. Blow-Fill-Seal Technology By Product Insights & Trends5.1. Product Dynamics & Market Share, 2021 & 20285.2. Bottles5.3. Vials5.4. Ampoules5.5. Pre-Filled Syringes & InjectablesChapter 6. Blow-Fill-Seal Technology By Raw Material Insights & Trends6.1. Raw Material Dynamics & Market Share, 2021 & 20286.2. Polypropylene (PP)6.3. Polyethylene (PE)6.3.3. High-Density Polyethylene6.3.4. Low-Density Polyethylene (LDPE)Chapter 7. Blow-Fill-Seal Technology By End Use Insights & Trends7.1. End Use Dynamics & Market Share, 2021 & 20287.2. Pharmaceuticals7.3. OthersChapter 8. Blow-Fill-Seal Technology Market Regional Outlook8.1. Blow-Fill-Seal Technology Market share By Region, 2021 & 2028Chapter 9. Competitive Landscape9.1. Market Revenue Share By Manufacturers9.2. Manufacturing Cost Breakdown Analysis9.3. Mergers & Acquisitions9.4. Market positioning9.5. Strategy Benchmarking9.6. Vendor LandscapeChapter 10. Company Profiles RecipharmUnipharmaRommelagUnicep PackagingCatalentThe Ritedose CorporationLyondellbasellWeiler EngineeringNupharma GroupBirgi Mefar Group. For more information about this report visit https://www.researchandmarkets.com/r/1a9cds CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The global Luxury Handbag Market size is expected to reach USD 94.00 billion by 2028, according to a new report by Million Insights. It is expected to expand at a CAGR of 5.3% from 2021 to 2028.
Nordic Entertainment Group (NENT Group) is set to produce two major English-language films every year, kicking off with “Hilma,” a biopic of the revolutionary Swedish artist and feminist pioneer Hilma af Klint, starring Lena Olin (“Enemies”). Lasse Hallström (‘The Cider House Rules”), one of Sweden’s most celebrated directors, is on board to write and direct […]
Technology stocks are weighing on the S&P 500 as investors bet on stocks that will benefit from the economy reopening.
The "Laboratory Information Management System Market Size, Share & Trends Analysis Report by Product, by Component, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
The "Global In Situ Hybridization (ISH) Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
Group of Seven countries should invest $1 trillion per year until 2030 to ensure a strong and sustainable economic recovery from the pandemic, according to a report that was requested by British Prime Minister Boris Johnson. U.S. President Joe Biden is expected to join other G7 leaders at a G7 summit in Cornwall, southern England, on June 11-13. "At the heart of the proposed vision for the economic response to the pandemic is a coordinated global programme of investment for recovery, reconstruction and transformation that can boost all forms of capital – physical, human, natural and social," Nicholas Stern, professor of economics at the London School of Economics, said in the report.
Major players in the lateral flow immunoassay (LFIA) based rapid test market are Abbott Laboratories, F. Hoffmann-La Roche, Danaher Corporation, Siemens AG, Becton, Dickinson and Company, bioMérieux, Bio-Rad Laboratories, Thermo Fisher Scientific, QIAGEN NV, and Hologic Inc.New York, May 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Lateral Flow Immunoassay (LFIA) Based Rapid Test Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06071097/?utm_source=GNW The global lateral flow immunoassay (lfia) based rapid test market is expected to grow from $5.768 billion in 2020 to $6.136 billion in 2021 at a compound annual growth rate (CAGR) of 6.4%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $9.136 billion in 2025 at a CAGR of 10%.The lateral flow immunoassay (LFIA) based rapid test market consists of sales of devices and equipment used to run lateral flow immunoassays (LFIA) based rapid test and related services by companies that develop lateral flow immunoassays (LFIA) based rapid test equipment. These are testing devices used to assess the existence of a target, such as pathogens or biomarkers, in samples obtained from the human body or animals, or pollutants in water sources, food or animal feed.Companies are collaborating to launch new products. In May 2020, Lateral Flow Diagnostic Company Mologic Ltd., which has teamed up with Biosure Ltd., the developer of the only CE approved HIV home testing kit, to develop a COVID-19 antibody self-test. The companies combine Mologic’s validated IgG lateral flow test strip with Biosure’s test kit. In July 2020, MP Biomedicals Asia Pacific Pte Ltd collaborated with a Singapore company A*STAR to create the ASSURE® SARS-CoV-2 IgG / IgM rapid antibody test kit to detect IgG and IgM antibodies in a person infected with SARS-CoV-2. The kit delivers precise results in very less time as less as 15 minutes and uses the lateral flow method.The lateral flow immunoassay (LFIA) based rapid test market covered in this report is segmented by technique into competitive assay; sandwich assay; multiplex detection assay. It is also segmented by end user into hospital and clinic; diagnostic laboratory; home care; others, and by application into infectious disease; pregnancy and fertility; toxicology; others.In April 2020, True Diagnostics, a leading US-based Point of Care (POC) company, partnered with Veravas and Infectolab Americas to create and distribute a fast, point-of-care immunoassay for SARS-CoV-2, the VeraTest SARS-CoV-2 IgA / IgG Fast Test will be developed to detect immunoglobulin A and immunoglobulin G antibodies to SARS-CoV-2 in the blood within 15 minutes.The test combines True Diagnostics, TrueDx lateral flow immunoassay technology with Veravas, VeraPrep clean and VeraPrep capture technologies designed to remove cross-reaction antibodies and ensure the detection of only SARS-CoV-2-specific antibodies.Veravas is an emerging US-based diagnostic company. Infectolab Americas is a US-based laboratory specialized in the lab testing for tick-borne disease.The demand for point-of-care testing under home care settings is expected to drive the Lateral Flow Immunoassay (LFIA) Based Rapid Test market.Point-of-care (POCT) testing is essential for rapid on-site diagnosis and treatment.The most important features for current POCT diagnostic systems are a quick analysis time with a test-to-answer format.Lateral flow immunoassays (LFIA) are widely used as POCTs due to their speed and precision, simplicity and low cost.For instance, the recent outbreak of coronavirus disease (COVID-19) has increased the significance of these devices to rapid screening and surveillance.Acro Biotech COVID-19 Rapid POC CE-IVD is a lateral flow immunoassay that quantifiably assesses the existence of patient-generated IgG and IgM antibodies to SARS-CoV-2, the causative agent of novel coronaviral disease COVID-19.These antibodies may be detected in whole blood, serum or plasma samples in the test cassette. OZO has developed three different variations of its products using the Latex Enhanced Lateral Flow Immunoassays (LFIAs) method for testing COVID-19. Therefore, the need for point-of-care testing under home care settings is expected to drive the Lateral Flow Immunoassay (LFIA) Based Rapid Test market.Low sensitivity of Lateral Flow Immunoassay (LFIA) Based Rapid Test is expected to limit the market. The sensitivity of the test is mainly the ability of the test to correctly identify those with the disease, which is low for Lateral Flow Immunoassay (LFIA) Based Rapid Test compared to other methods that may, in some cases, require a re-test for confirmation. according to a study conducted by researchers, including those from the Harvard medical school in the USA and also the University of British Columbia, Canada. The medical databases and preprint servers were searched from January 1 to April 30 2020, for studies measuring the sensitivity and specificity of the Covid-19 antibody test compared to the control test. It had been found that pooled sensitivities were consistently lower for the lateral flow immunoassay (LFIA) test compared to other test methods. The low level of sensitivity is anticipated to restrain the market growth for Lateral Flow Immunoassay (LFIA) based rapid test.Read the full report: https://www.reportlinker.com/p06071097/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
Dublin, May 10, 2021 (GLOBE NEWSWIRE) -- The "Cervical Dysplasia Market Share, Size, Trends, Industry Analysis Report, By Type; By End-Use, By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering. The global cervical dysplasia market size is expected to reach USD 936.4 million by 2028 according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.The rising prevalence of cervical cancer and awareness regarding its early diagnosis is the key cervical dysplasia industry impacting factors. As per the report published by World Health Organization, in 2018, worldwide there were around 5, 70,000 new cases of cervical cancer, and more than 3,11,000 deaths were recorded. It also reported that HPV is the most common causal factor for cervical dysplasia among women.Moreover, Cervical Awareness Month was introduced by the U.S. Congress, in 2019, to declare the month of January dedicated to the patients suffering from cervical cancer in the market. National Cervical Cancer Coalition under government control was responsible to highlight issues related to disease and the importance of early diagnosis. These government-supported initiatives are bound to increase awareness regarding disease screening and are anticipated to boost the market growth for cervical dysplasia.Market participants such as Qiagen N.V., Abbott Laboratories, Hologic, Inc., Quest Diagnostics, DYSIS Medical Ltd, Micromedic Technologies Ltd., OncoHealth Corporation, Inc., CooperSurgical Inc., and Roche are some of the key players operating in the global market for cervical dysplasia. The companies in the marketplace for cervical dysplasia are focussing on collaborations and agreement to survive in the highly regulated market with huge patient unmet needs.For instance, in January 2020, both Japan pharmaceutical giants ASKA Pharmaceutical and KinoPharma entered into a collaborative agreement for the development and commercialization of drug candidates for cervical dysplasia in the market, which is under preclinical phase under KinoPharma. Under the agreement, ASKA would obtain exclusive rights to sell the drug in the Japanese market and will help later in co-developing potential drug candidates and KinoPharma in return will receive upfront payments for the exclusive licensing.Earlier, in July 2019, Roche expanded its portfolio of offerings under the Global Access Program to include HPV, and Mycobacterium tuberculosis diagnostic products for the emerging countries, particularly in countries where the prevalence of HPV is highest. This expansion is an attempt towards cost-effective treatments for cervical dysplasia in resource constraint countries and to implement multiple large-scale programs.The publisher has segmented the cervical dysplasia market report on the basis of type, end-use, and region:Cervical Dysplasia, by Type Outlook Diagnostic TestsHPV TestPap Smear TestBiopsy TestDiagnostic DevicesColposcope Cervical Dysplasia, by End-Use Outlook HospitalsDiagnostic CentersAmbulatory Surgical Centers Cervical Dysplasia, by Regional Outlook North AmericaU.S.CanadaEuropeFranceGermanyUKItalySpainNetherlandsAustriaAsia PacificChinaIndiaJapanMalaysiaSouth KoreaIndonesiaCentral & South AmericaMexicoBrazilArgentinaMiddle East & AfricaUAESaudi ArabiaIsraelSouth Africa Key Topics Covered: 1. Introduction1.1. Report Description1.2. Stakeholders2. Executive Summary2.1. Market Highlights3. Research Methodology3.1. Overview3.2. Data Sources4. Cervical Dysplasia Market Insights4.1. Cervical Dysplasia - Industry snapshot4.2. Cervical Dysplasia Market Dynamics4.3. Porter's Five Forces Analysis4.4. PESTLE Analysis4.5. Cervical Dysplasia Market Industry trends5. Cervical Dysplasia Market Assessment by Type5.1. Key Findings5.2. Introduction5.3. Diagnostic Tests5.4. Diagnostic Devices5.5. Colposcope6. Global Cervical Dysplasia Market, by End-Use6.1. Key Findings6.2. Introduction6.3. Hospitals6.4. Diagnostic Centers6.5. Ambulatory Surgical Centers7. Cervical Dysplasia Market Assessment by Geography7.1. Key findings7.2. Introduction7.3. Cervical Dysplasia Market - North America7.4. Cervical Dysplasia Market - Europe7.5. Cervical Dysplasia Market - Asia-Pacific7.6. Cervical Dysplasia Market - Middle East & Africa7.7. Cervical Dysplasia Market - Latin America8. Competitive Landscape8.1. Expansion and Acquisition Analysis8.2. Partnerships/Collaborations/Agreements/Exhibitions9. Company Profiles9.1. Qiagen N.V.9.2. Abbott Laboratories9.3. Hologic, Inc.9.4. Quest Diagnostics9.5. DYSIS Medical Ltd.9.6. Micromedic Technologies Ltd.9.7. OncoHealth Corporation, Inc.9.8. CooperSurgical Inc.9.9. Roche9.10. Karl Kaps GmbH & Co. KG For more information about this report visit https://www.researchandmarkets.com/r/4gy466 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The "Polyurethane Microspheres Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
Hotel Chocolat on Monday said that online demand has been high, and full-year trading is set to come in ahead of expectations. The retailer and chocolate maker said despite stores being closed for most of the eight weeks to April 25, it still managed to record 60% annual sales growth. The AIM-listed chain said growth at the business was “driven largely by its digital channels and subscription products which further demonstrates the strength of the company's omni-channel sales model”.
The "Conveyor belt Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.
The Province of Buenos Aires (the "Province") today announced that it has further extended the expiration of its invitation (the "Invitation") made to holders of certain eligible bonds (the "Eligible Bonds") listed in the Invitation Memorandum dated April 24, 2020 (as amended and supplemented from time to time, the "Invitation Memorandum") to submit orders to exchange their Eligible Bonds for new bonds pursuant to the terms and subject to the conditions described in the Invitation Memorandum from 5:00 p.m., Central European Time, on May 7, 2021, to 5:00 p.m., Central European Time, on May 21, 2021 (the "Expiration"), unless further extended or early terminated. Accordingly, assuming that the Province, among other things, does not further extend the Expiration or terminate the Invitation early, the Invitation Period (as defined in the Invitation Memorandum) is extended through the new Expiration, the Results Announcement Date (as defined in the Invitation Memorandum) shall be on May 24, 2021 or as early as practicable thereafter, and the Execution Date, the Effective Date and the Settlement Date, each as defined in the Invitation Memorandum, shall be on May 28, 2021 or as early as practicable thereafter.
Sony is selling a lot of PlayStation 5s, but it may be some time before the console hits its true sales potential.
McIlroy’s 19th PGA Tour title lifted him to seventh in the world rankings just 10 days before the year’s second major.
HGC Global Communications Limited (HGC), a fully-fledged fixed-line operator and ICT service provider with extensive local and international network coverage, services and infrastructure, today announced the provision of one-stop managed telecom and ICT services to CU Coding Ltd. (CUC).
Lockdowns have led to 'maladaptive coping behaviours, such as comfort eating and drinking'.
The 20-year-old limped off in the victory over West Brom on Sunday to make him a doubt to face Chelsea